Arcus Biosciences Inc., a global biopharmaceutical company based in Hayward, California, has announced the approval of new employment inducement grants. The Compensation Committee of the company's Board of Directors has granted a new employee options to purchase 2,850 shares of Arcus Biosciences' common stock at an exercise price of $8.63 per share, reflecting the closing price as of June 23, 2025. Additionally, the employee received restricted stock units to acquire 1,450 shares. These equity awards are part of the company's 2020 Inducement Plan, which operates under the "inducement exception" of the NYSE Listed Company Manual Rule 303A.08.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.